Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

In this episode, I talked with Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, a Copenhagen-based biotech developing GIPR antagonists in the obesity space.

Richard’s career began in the NHS, where he spent five years practicing acute medicine and intensive care—until the moment he realized he couldn’t picture himself doing the same thing for the next 30 years. That realization sparked a pivot that many physicians quietly wrestle with: leaving behind the security of the ward for the uncertainty of industry.

Richard also shares what it was like to walk away from a stable VP role at Bayer during a restructuring, take an intentional career break, and use those months to reflect on what really mattered before joining Antag Therapeutics. We talk about the shift from big pharma to biotech, what he learned from leading through severe stakeholder misalignment, and why authentic communication matters more than management theory when things get messy.

And yes—there’s a light-hearted detour into Berlin life, bad currywurst, and how to tell when it’s time to make serious changes in your team.

Here’s What You’re In For

  1. What makes Antag Therapeutics’ culture unique
  2. The hardest leadership call: deciding when the problem is you vs them
  3. The recruitment ghosting story that every hiring manager should hear


Timestamps

02:08 – Leaving the NHS: deciding what he could be “happily bored with”

04:00 – Landing his first pharma job at Bayer in drug safety

09:33 – Overview of Antag Therapeutics and GIPR vs GLP-1

13:20 – Leaving Bayer and taking a sabbatical to reset

17:08 – What it’s like to work at Antag Therapeutics—and what he looks for in candidates

18:46 – The toughest chapter: extreme stakeholder misalignment in dermatology

25:16 – Leadership lessons: firing, feedback, and the “benefit of the doubt”

29:00 – Why managers struggle to act fast—and how structure slows decisions

31:48 – Richard’s worst recruitment experience: being ghosted by agencies


About Richard

Richard Nkulikiyinka, is the Chief Medical Officer of Antag Therapeutics, a biotech developing GIPR antagonists within the Obesity space. A UK-trained physician, he spent five years practicing in acute medicine and intensive care within the NHS - this is also where he developed his dry sense of humour - and now he transitioned into the biopharmaceutical industry, where he has built over 17 years of experience.

Prior to joining Antag, Richard served as Vice President in Clinical Development at Bayer Pharma, where he played a central role in advancing four drugs to approval. He is now ein Berliner - where we often meet for clubbing and currywurst.

Connect with Richard:

  1. LinkedIn: https://www.linkedin.com/in/richard-nkulikiyinka-66336014/
  2. Website: https://antagtx.com/


About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment, I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.

Connect with me:

  1. LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/
  2. Website: https://www.discera-search.com/


Opinions and comments expressed by the guest do not represent the company and are fully their own.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(71)

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Juni 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Maj 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Maj 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Maj 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mars 42min

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

In this episode, I talked with Volker Wacheck, SVP & Head of Clinical Development at Taiho Oncology, where he shared how a PI role in Vienna led him into industry, and why the hardest part wasn’t leav...

9 Mars 29min

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

In this episode, I talked with Dr. Dena Grayson, a physician–scientist with over two decades in biotech drug development. At the time of this recording, she was SVP and Head of Clinical Development at...

24 Feb 31min

Populärt inom Business & ekonomi

badfluence
framgangspodden
varvet
rss-borsens-finest
avanzapodden
uppgang-och-fall
svd-tech-brief
rss-svart-marknad
bathina-en-podcast
lastbilspodden
rss-dagen-med-di
fill-or-kill
24fragor
rss-inga-dumma-fragor-om-pengar
borsmorgon
dynastin
rss-den-nya-ekonomin
rikatillsammans-om-privatekonomi-rikedom-i-livet
rss-kort-lang-analyspodden-fran-di
borslunch-2